Given that only about 1/3 of anti-MDA5+DM may develop RP-ILD after disease onset in our cohort and the previous report, early recognition of patients with high RP-ILD risk is particularly important in halting disease progression and improving prognosis in anti-MDA5+DM. Here, IFIH1 is linked to interstitial lung disease.